We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Methods Rapidly Diagnoses Huntington's Disease

By LabMedica International staff writers
Posted on 23 Jan 2019
People with Huntington's disease suffer from jerky body movements and decreasing mental abilities. More...
The condition usually leads to death 15 to 20 years after diagnosis. The cause of the disease is a region in the Huntingtin gene (HTT) that is absent in healthy people.

A novel lab-on-chip system, termed µLAS (µLAboratory for DNA Separation) has been designed which is composed of two identical side-by-side channels operated with the same actuation parameters, so as to characterize a sample with respect to a reference DNA ladder in real time.

Scientists from the University of Lausanne (Lausanne, Switzerland) extracted the DNA from blood cells, amplified the concerned region and determined its size with a newly developed chip. The chip holds two small, funnel-shaped chambers a fraction of a millimeter wide. Voltage and pressure are applied to these chambers so as to separate the electrically charged DNA fragments according to their size. The smaller fragments are pushed down the funnel much more than the large ones. By adding a fluorescent dye, the team easily detected the exact position of the fragments under a microscope and deduced their length.

The variable length of the DNA fragments is caused by a repetition of three nucleotides of the genetic code (CAG), typical for trinucleotide diseases like Huntington's. The mutation leads to destructive changes in the encoded protein that are currently not fully understood, but the protein produced by the mutated gene is known to be toxic to brain cells. Healthy people have 35 or less of these repeats, whereas most patients have 40 or more. Knowing the exact size is important for forecasting and managing the incurable disease. The scientists detected heterogeneous allele lengths in eight samples from myotonic dystrophy type 1 and Huntington disease patients with up to 750 CAG/CTG repeats in five minutes or less.

The high sensitivity of the method allowed us to minimize the number of amplification cycles and thus reduce amplification artifacts without compromising the detection of the expanded allele. These results suggest that µLAS can speed up routine molecular biology applications of repetitive sequences and may improve the molecular diagnostic of expanded repeat disorders. Huntington's disease is only one of over twenty known trinucleotide diseases. Others are spinocerebellar ataxia, fragile X syndrome, myotonic dystrophy and Friedreich's ataxia. Currently there is no treatment available for these hereditary diseases. The study was published on January 10, 2019, in the journal Scientific Reports.

Related Links:
University of Lausanne


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.